Bicycle Therapeutics (BCYC) Other Non-Current Liabilities (2018 - 2026)
Bicycle Therapeutics (BCYC) posted Other Non-Current Liabilities of $973000.0 for Q1 2026, down 5.72% on a QoQ basis from $1.0 million in Q4 2025, and down 12.81% year-over-year from $1.1 million in Q1 2025.
Bicycle Therapeutics (BCYC) Other Non-Current Liabilities (2018 - 2026) Analysis & Trends
Bicycle Therapeutics' Other Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $973000.0 for Q1 2026.
- Quarterly Other Non-Current Liabilities fell 12.81% year-over-year to $973000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $973000.0 (down 12.81% YoY) and the FY2025 annual result came in at $1.0 million, down 7.94% from the prior year.
- Other Non-Current Liabilities was $973000.0 for Q1 2026 at Bicycle Therapeutics, down from $1.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $6.0 million in Q3 2024 and bottomed at $973000.0 in Q1 2026.
- A 5-year average of $3.1 million and a median of $3.4 million in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities soared 38.16% — and 2025, when it tumbled 81.67%.
- Bicycle Therapeutics' Other Non-Current Liabilities stood at $3.8 million in 2022, then climbed by 19.59% to $4.6 million in 2023, then sank by 75.52% to $1.1 million in 2024, then slipped by 7.94% to $1.0 million in 2025, then fell by 5.72% to $973000.0 in 2026.
- Business Quant data shows BCYC's Other Non-Current Liabilities at $973000.0 in Q1 2026, $1.0 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Bicycle Therapeutics | 289.88 Mn | 289.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 973,000.00 |
| Dec 31, 2025 | 1.03 Mn |
| Sep 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 1.14 Mn |
| Mar 31, 2025 | 1.12 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | 5.96 Mn |
| Jun 30, 2024 | 4.70 Mn |
| Mar 31, 2024 | 4.61 Mn |
| Dec 31, 2023 | 4.58 Mn |
| Sep 30, 2023 | 4.32 Mn |
| Jun 30, 2023 | 4.33 Mn |
| Mar 31, 2023 | 4.08 Mn |
| Dec 31, 2022 | 3.83 Mn |
| Sep 30, 2022 | 3.16 Mn |
| Jun 30, 2022 | 3.26 Mn |
| Mar 31, 2022 | 3.36 Mn |
| Dec 31, 2021 | 3.28 Mn |
| Sep 30, 2021 | 3.04 Mn |
| Mar 31, 2021 | 2.81 Mn |